Adam Lerner MD
Professor, Hematology & Medical Oncology
Professor, Pathology & Laboratory Medicine
650 Albany St | (617) 638-7504adam.lerner@bmc.org
lernwara@bu.edu
Sections
Hematology & Medical Oncology
Centers
BU-BMC Cancer Center
Evans Center for Interdisciplinary Biomedical Research
Biography
Dr. Lerner is a Professor of Medicine, Pathology and Laboratory Medicine at Chobanian and Avedisian School of Medicine (BUSM) and a medical oncologist at Boston Medical Center (BMC). He received his MD from Yale School of Medicine, followed by an internal medicine residency at Boston City Hospital. He did his fellowship in Medical Oncology at the Dana Farber Cancer Institute, Harvard Medical School, and subsequently remained there while carrying out research in the cellular and molecular biology of T lymphocytes. In 1996, he joined the Hematology/Oncology Section at Boston Medical Center. His laboratory research has focused in two areas: 1) The therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in lymphoid malignancies; 2) The mechanism by which a novel adapter protein (BCAR3/ AND-34) modulates focal adhesion complex signaling in mesenchymal, epithelial and hematopoietic cells. Clinically, Dr. Lerner cares for patients with hematologic malignancies, cutaneous malignancies and sarcomas.
Expertise includes: CLL; Leukemia; Lymphoid malignancies; Sarcoma; Breast cancer; cAMP signaling.
Other Positions
Education
MD, Yale University School of Medicine
AB, Amherst College
Publications
Halpin M, Lerner A, Sagar M, Govender P, Shah B, Weinberg J, Sarosiek S, Sloan JM. A prospective, single-center, randomized phase 2 trial of etoposide in severe COVID-19. medRxiv. 2023 Jun 06. PMID: 37333402.
Published on 3/9/2022Hughes DM, Henshaw L, Blevins F, Edwards C, Lerner A, Sloan JM, Sanchorawala V. Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis. Clin Lymphoma Myeloma Leuk. 2022 Aug; 22(8):566-568. PMID: 35367193.
Published on 2/25/2022Milrod CJ, Mann M, Blevins F, Hughes D, Patel P, Li KY, Lerner A, Sanchorawala V, Sloan JM. Underrepresentation of Black participants and adverse events in clinical trials of lenalidomide for myeloma. Crit Rev Oncol Hematol. 2022 Apr; 172:103644. PMID: 35227897.
Published on 5/27/2021Milrod CJ, Blevins F, Hughes D, Lerner A, Sarosiek S, Sanchorawala V, Sloan JM. Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs. Blood. 2021 05 27; 137(21):2987-2989. PMID: 33728443.
Published on 9/8/2020Prilutskiy A, Kritselis M, Shevtsov A, Yambayev I, Vadlamudi C, Zhao Q, Kataria Y, Sarosiek SR, Lerner A, Sloan JM, Quillen K, Burks EJ. SARS-CoV-2 Infection-Associated Hemophagocytic Lymphohistiocytosis. Am J Clin Pathol. 2020 09 08; 154(4):466-474. PMID: 32681166.
Published on 5/27/2020Dennis M, Maoz A, Cirstea D, Patel A, Lerner A, Sarosiek S. Treatment disparities in minority groups with multiple myeloma at a safety-net hospital. Leuk Lymphoma. 2020 10; 61(10):2507-2510. PMID: 32460648.
Published on 1/31/2019Leiva O, McMahon L, Sloan JM, Lee J, Lerner A. Recognition of hemophagocytic lymphohistiocytosis in sickle cell vaso-occlusive crises is a potentially lifesaving diagnosis. Haematologica. 2019 04; 104(4):e167-e169. PMID: 30705096.
Published on 1/15/2018Min MS, Al-Haseni A, Succaria F, Goldberg L, Lerner A, Sahni D. Anaplastic large cell lymphoma localized to the left breast years after radiotherapy for breast cancer. Dermatol Online J. 2018 Jan 15; 24(1). PMID: 29469762.
Published on 9/1/2017de Medeiros AS, Wyman AR, Alaamery MA, Allain C, Ivey FD, Wang L, Le H, Morken JP, Habara A, Le C, Cui S, Lerner A, Hoffman CS. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays. Cell Signal. 2017 Dec; 40:73-80. PMID: 28867658.
Published on 8/30/2017Duvic M, Bates SE, Piekarz R, Eisch R, Kim YH, Lerner A, Robak T, Samtsov A, Becker JC, McCulloch W, Waksman J, Whittaker S. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. Leuk Lymphoma. 2018 04; 59(4):880-887. PMID: 28853310.